“…Consequently, there is a lack of independent analyses of the current and future savings from the use of biosimilars. Several authors reported estimates from the EGA where savings could attain up to €1.6 billion conditional on a 20 % price reduction for five patent-expired biologicals [3, 5, 8, 22]. This rough estimate does not provide information based on the currently available biosimilars but ratter based on expectation of their apparition.…”